Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
12.1 (1y: -7%)
Market Cap 7.18 B P/E(ttm)
Enterprise Value 7.18 B P/B 11.40
ELN- NYSE (USA)
Elan Corp PLC
  • Currently 1/5
Business Predictability Rank: 1-Star (On Watch)
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$12.10
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyÂ’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry		 vs
history
Cash to Debt 0.999
ELN's Cash to Debt is ranked lower than
76% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ELN: 0.999 )
ELN' s 10-Year Cash to Debt Range
Min: 0.23   Max: 1
Current: 1
0.23
1
Equity to Asset 0.317
ELN's Equity to Asset is ranked lower than
76% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.54 vs. ELN: 0.317 )
ELN' s 10-Year Equity to Asset Range
Min: -0.42   Max: 0.32
Current: 0.32
-0.42
0.32
F-Score: 3
Z-Score: 3.16
M-Score: -4.35
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyÂ’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry		 vs
history
Operating margin (%) -188750.00
ELN's Operating margin (%) is ranked higher than
60% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -52.55 vs. ELN: -188750.00 )
ELN' s 10-Year Operating margin (%) Range
Min: -188750   Max: 67.4
Current: -188750
-188750
67.4
Net-margin (%) -68700
ELN's Net-margin (%) is ranked higher than
50% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -55.70 vs. ELN: -68700 )
ELN' s 10-Year Net-margin (%) Range
Min: -68700   Max: 45
Current: -68700
-68700
45
ROE (%) -22.2
ELN's ROE (%) is ranked lower than
73% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -16.60 vs. ELN: -22.2 )
ELN' s 10-Year ROE (%) Range
Min: -2269.8   Max: 69.9
Current: -22.2
-2269.8
69.9
ROA (%) -8.4
ELN's ROA (%) is ranked lower than
70% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -14.40 vs. ELN: -8.4 )
ELN' s 10-Year ROA (%) Range
Min: -76.6   Max: 32
Current: -8.4
-76.6
32
ROC (Joel Greenblatt) (%) -63.40
ELN's ROC (Joel Greenblatt) (%) is ranked lower than
86% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -0.20 vs. ELN: -63.40 )
ELN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -195.9   Max: 745.3
Current: -63.4
-195.9
745.3
Revenue Growth (%) -100
ELN's Revenue Growth (%) is ranked higher than
74% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. ELN: -100 )
ELN' s 10-Year Revenue Growth (%) Range
Min: -100   Max: 15.7
Current: -100
-100
15.7
EPS Growth (%) -10
ELN's EPS Growth (%) is ranked lower than
94% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. ELN: -10 )
ELN' s 10-Year EPS Growth (%) Range
Min: -45.2   Max: -3.9
Current: -10
-45.2
-3.9
» ELN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

ELN Guru Trades in Q2 2012

Louis Moore Bacon 50,000 sh (New)
Eric Mindich 1,000,000 sh (New)
George Soros 4,583,900 sh (+17.54%)
Michael Price 935,000 sh (unchged)
Robert Bruce 165,900 sh (unchged)
Vanguard Health Care Fund 8,894,800 sh (unchged)
George Soros 300,000 sh (unchged)
Jim Simons Sold Out
Ray Dalio 39,872 sh (-52.23%)
Steven Cohen 24,080 sh (-77.14%)
» More
Q3 2012

ELN Guru Trades in Q3 2012

Jim Simons 612,200 sh (New)
Ray Dalio 559,172 sh (+1302.42%)
Louis Moore Bacon 75,000 sh (+50%)
Vanguard Health Care Fund 9,234,600 sh (+3.82%)
Eric Mindich 1,000,000 sh (unchged)
George Soros 300,000 sh (unchged)
Robert Bruce 165,900 sh (unchged)
Michael Price 900,000 sh (-3.74%)
Steven Cohen 10,706 sh (-55.54%)
George Soros 1,250,000 sh (-72.73%)
» More
Q4 2012

ELN Guru Trades in Q4 2012

Steven Cohen 28,892 sh (+169.87%)
Jim Simons 1,579,000 sh (+157.92%)
Ray Dalio 1,085,883 sh (+94.19%)
Vanguard Health Care Fund 10,234,600 sh (+10.83%)
Michael Price 900,000 sh (unchged)
Robert Bruce 165,900 sh (unchged)
Louis Moore Bacon Sold Out
Eric Mindich Sold Out
George Soros 400,000 sh (-68%)
» More
Q1 2013

ELN Guru Trades in Q1 2013

Andreas Halvorsen 9,372,400 sh (New)
Seth Klarman 9,126,227 sh (New)
Jean-Marie Eveillard 2,323,819 sh (New)
Steven Cohen 401,918 sh (+1291.1%)
Vanguard Health Care Fund 19,470,300 sh (+90.24%)
Michael Price 1,100,000 sh (+22.22%)
Robert Bruce 165,900 sh (unchged)
George Soros Sold Out
Ray Dalio Sold Out
Jim Simons 161,500 sh (-89.77%)
» More
» Details

Insider Trades

Latest Guru Trades with ELN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Seth Klarman 2013-03-31 New Buy3.5%$9.4 - $12 $ 12.0711%9126227
Vanguard Health Care Fund 2013-03-31 Add 90.24%0.43%$9.4 - $12 $ 12.0711%19470300
Michael Price 2013-03-31 Add 22.22%0.31%$9.4 - $12 $ 12.0711%1100000
Ray Dalio 2013-03-31 Sold Out 0.11%$9.4 - $12 $ 12.0711%0
Jean-Marie Eveillard 2013-03-31 New Buy0.09%$9.4 - $12 $ 12.0711%2323819
George Soros 2013-03-31 Sold Out 0.05%$9.4 - $12 $ 12.0711%0
George Soros 2012-12-31 Reduce -68%0.15%$9.56 - $11.06 $ 12.0717%400000
Ray Dalio 2012-12-31 Add 94.19%0.05%$9.56 - $11.06 $ 12.0717%1085883
George Soros 2012-09-30 Reduce -72.73%0.71%$10.71 - $14.57 $ 12.070%1250000
Ray Dalio 2012-09-30 Add 1302.42%0.08%$10.71 - $14.57 $ 12.070%559172
George Soros 2012-06-30 Add 17.54%0.14%$12.79 - $15 $ 12.07-12%4583900
Ray Dalio 2012-06-30 Reduce -52.23%0.01%$12.79 - $15 $ 12.07-12%39872
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/B 11.40
ELN's P/B is ranked lower than
75% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. ELN: 11.40 )
ELN' s 10-Year P/B Range
Min: 0.32   Max: 1435
Current: 11.4
0.32
1435
P/S 901.50
ELN's P/S is ranked higher than
62% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 6.90 vs. ELN: 901.50 )
ELN' s 10-Year P/S Range
Min: 0.45   Max: 8.11639E+16
Current: 901.5
0.45
8.11639E+16
PFCF 460.30
ELN's PFCF is ranked lower than
54% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 24.02 vs. ELN: 460.30 )
ELN' s 10-Year PFCF Range
Min: 1.73   Max: 459.2
Current: 460.3
1.73
459.2
EV-to-EBIT 13.3
ELN's EV-to-EBIT is ranked lower than
84% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 14.61 vs. ELN: 13.3 )
ELN' s 10-Year EV-to-EBIT Range
Min: 7.7   Max: 348.8
Current: 13.3
7.7
348.8

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 50.3
ELN's Price/Net Current Asset Value is ranked lower than
96% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 32.60 vs. ELN: 50.3 )
ELN' s 10-Year Price/Net Current Asset Value Range
Min: 6   Max: 215
Current: 50.3
6
215
Price/Tangible Book 13.7
ELN's Price/Tangible Book is ranked higher than
93% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. ELN: 13.7 )
ELN' s 10-Year Price/Tangible Book Range
Min: 11.4   Max: 41.8
Current: 13.7
11.4
41.8
Earnings Yield (Greenblatt) 7.50
ELN's Earnings Yield (Greenblatt) is ranked lower than
80% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. ELN: 7.50 )
ELN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 13
Current: 7.5
0.3
13
Forward Rate of Return (Yacktman) -2.21
ELN's Forward Rate of Return (Yacktman) is ranked higher than
74% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -4.65 vs. ELN: -2.21 )
ELN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -16.3   Max: -2.4
Current: -2.21
-16.3
-2.4

Business Description

Elan Corporation, plc, an Irish public limited company, is a neuroscience-based biotechnology company. It was incorporated as a private limited company in Ireland in December 1969 and became a public limited company in January 1984. It is a neuroscience-based biotechnology company and its business is organized into two business units: BioNeurology and Elan Drug Technologies (EDT). On September 16, 2011, it announced the completion of the merger between Alkermes, Inc. and EDT. In BioNeurology, the company is developing therapies for serious diseases that have long been considered intractable, including MS, Alzheimer's disease and Parkinson's disease. EDT develops and manufactures pharmaceutical products that deliver clinically meaningful benefits to patients, using its experience and proprietary drug technologies in collaboration with pharmaceutical companies. Tysabri, a treatment for relapsing forms of MS, competes mainly with Avonex, Betaseron(r), Berlex. The pharmaceutical industry is subject to significant regulation by international, national, state and local governmental regulatory agencies.
Company Website
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:EAN.Germany, DRX.Germany

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial